Kura Oncology, Inc. (NASDAQ:KURA) SVP Sells $38,948.63 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Kura Oncology Price Performance

Shares of KURA stock traded down $0.14 during trading hours on Tuesday, hitting $7.77. 1,544,944 shares of the company’s stock were exchanged, compared to its average volume of 1,497,249. The stock’s 50-day moving average is $9.23 and its 200-day moving average is $15.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market cap of $604.20 million, a price-to-earnings ratio of -3.29 and a beta of 0.81. Kura Oncology, Inc. has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the business posted ($0.50) earnings per share. As a group, research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. grew its position in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after acquiring an additional 2,076 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after buying an additional 3,092 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Kura Oncology by 251.5% during the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after buying an additional 58,422 shares during the period. Quarry LP acquired a new stake in Kura Oncology in the 2nd quarter worth about $196,000. Finally, The Manufacturers Life Insurance Company raised its stake in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares in the last quarter.

Analysts Set New Price Targets

KURA has been the subject of a number of research analyst reports. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Finally, Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.